Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Inotuzumab Ozogamicin for B-ALL
NCT05016947Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in B cell acute lymphoblastic leukemia (B-ALL) and B cell lymphoma, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 9 months. Started Sep 2021; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT05016947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05016947.